Treatment groups will be identical to those in HGT-MLD-070, ie, patients assigned to Cohort 1 in Study HGT-MLD-070 will continue to receive a dose of 10 mg, patients assigned to Cohort 2 in Study HGT-MLD-070 will continue to receive a dose of 30 mg, and patients assigned to Cohorts 3 and 4 in Study HGT-MLD-070 will continue to receive a dose of 100 mg. Patients in Cohort 4 are to exclusively receive drug product produced with Process B in Study HGT-MLD-070 and will continue receiving this drug product in this study. Patients enrolled in this study from Cohorts 1 to 3 in Study HGT-MLD-070 were transitioned to Process B after all necessary approvals were obtained.